

NEWS RELEASE



10th August, 2018

Presentations on NS-065/ NCNP-01 at the 23rd International Annual Congress of the World Muscle Society

Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto City; President, Shigenobu Maekawa) announced today that presentations on NS-065/ NCNP-01* which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD) will be given at the 23rd International Annual Congress of the World Muscle Society to be held in Mendoza, Argentina in October 2-6, 2018.

Schedule	16:00 – 17:30, 3rd October (Wed), 2018 (ATR)
Subject	Poster session: 1. A phase II, dose finding study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NS-065/NCNP-01 in boys with Duchenne muscular dystrophy 2. A Japanese phase I/II study of NS-065/NCNP-01, exon 53 skipping drug, in patients with Duchenne muscular dystrophy - a dose-finding study

* NS-065/NCNP-01 is a morpholino antisense oligonucleotide, which is expected to improve muscle function for DMD patients amenable to exon 53 skipping. It was co-discovered by Nippon Shinyaku and National Center of Neurology and Psychiatry (Kodaira City, Tokyo; President, Hidehiro Mizusawa, Corporate director, Shin'ichi Takeda) and is a drug candidate which is expected to be an option for DMD.